Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same author

Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change.

International journal of cancer·2026
Same author

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Oral oncology·2026
Same author

Refining adjuvant radiation therapy decision using a nomogram in major salivary gland carcinoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial.

Annals of surgery·2026

Related Experiment Video

Updated: Apr 12, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K

Adjuvant radiation for soft tissue sarcomas.

Colleen I Dickie1, Rick Haas1, Brian O'Sullivan1

  • 1From the Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 21, 2015
PubMed
Summary
This summary is machine-generated.

Adjuvant radiation therapy (RT) improves outcomes for soft tissue sarcoma (STS). This review details the "what, when, and why" of RT for extremity and retroperitoneal STS, focusing on pre- and postoperative applications.

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Related Experiment Videos

Last Updated: Apr 12, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Radiation Oncology

Background:

  • Limb-preservation surgery combined with radiotherapy achieves >90% local control for extremity soft tissue sarcoma (STS).
  • Local control rates for retroperitoneal sarcoma are lower (~60%) despite aggressive surgical and intensity-modulated radiotherapy (IMRT) approaches.
  • Adjuvant radiation therapy (RT) plays a crucial role in managing STS, particularly in challenging locations.

Purpose of the Study:

  • To review the indications for adjuvant RT in primary soft tissue sarcoma.
  • To discuss the optimal planning, delivery, timing, and rationale for adjuvant RT.
  • To focus on pre- and postoperative RT strategies for extremity and retroperitoneal STS following gross total resection.

Main Methods:

  • Literature review and synthesis of current evidence on adjuvant RT for STS.
  • Discussion of treatment paradigms for extremity and retroperitoneal STS.
  • Analysis of the 'what,' 'when,' and 'why' of adjuvant RT indications.

Main Results:

  • Extremity STS generally shows high local control with combined modality treatment.
  • Retroperitoneal STS presents unique challenges, with lower local control rates necessitating optimized adjuvant strategies.
  • Pre- and postoperative RT are key considerations for achieving maximal local control in both STS subtypes.

Conclusions:

  • Adjuvant RT is a critical component in the multidisciplinary management of soft tissue sarcoma.
  • Tailored RT approaches, considering timing and delivery, are essential for improving outcomes in both extremity and retroperitoneal STS.
  • Further research and standardized guidelines for adjuvant RT in STS are warranted.